Gene Therapy Market (By Indication: Acute Lymphoblastic Leukemia, Large B-cell Lymphoma; By Vector Type: Lentivirus; By Route of Administration) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Gene Therapy Market 

5.1. COVID-19 Landscape: Gene Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Gene Therapy Market, By Indication

8.1. Gene Therapy Market, by Indication, 2024-2033

8.1.1. Acute Lymphoblastic Leukemia (ALL)

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Inherited Retinal Disease

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Large B-cell Lymphoma

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. ADA-SCID

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Melanoma (lesions)

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Beta-Thalassemia Major/SCD

8.1.6.1. Market Revenue and Forecast (2021-2033)

8.1.7. Head & Neck Squamous Cell Carcinoma

8.1.7.1. Market Revenue and Forecast (2021-2033)

8.1.8. Peripheral arterial disease

8.1.8.1. Market Revenue and Forecast (2021-2033)

8.1.9. Spinal Muscular Atrophy (SMA)

8.1.9.1. Market Revenue and Forecast (2021-2033)

8.1.10. Others

8.1.10.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Gene Therapy Market, By Vector Type

9.1. Gene Therapy Market, by Vector Type, 2024-2033

9.1.1. Lentivirus

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. AAV

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. RetroVirus & gamma RetroVirus

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Modified Herpes Simplex Virus

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Adenovirus

9.1.5.1. Market Revenue and Forecast (2021-2033)

9.1.6. Non-viral Plasmid Vector

9.1.6.1. Market Revenue and Forecast (2021-2033)

9.1.7. Others

9.1.7.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Gene Therapy Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Indication (2021-2033)

10.1.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Indication (2021-2033)

10.1.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Indication (2021-2033)

10.1.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Indication (2021-2033)

10.2.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Indication (2021-2033)

10.2.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Indication (2021-2033)

10.2.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Indication (2021-2033)

10.2.5.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Indication (2021-2033)

10.2.6.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Indication (2021-2033)

10.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Indication (2021-2033)

10.3.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Indication (2021-2033)

10.3.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Indication (2021-2033)

10.3.5.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Indication (2021-2033)

10.3.6.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Indication (2021-2033)

10.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Indication (2021-2033)

10.4.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Indication (2021-2033)

10.4.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Indication (2021-2033)

10.4.5.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Indication (2021-2033)

10.4.6.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Indication (2021-2033)

10.5.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Indication (2021-2033)

10.5.3.2. Market Revenue and Forecast, by Vector Type (2021-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Indication (2021-2033)

10.5.4.2. Market Revenue and Forecast, by Vector Type (2021-2033)

Chapter 11. Company Profiles

11.1. REGENXBIO, Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Oxford BioMedica plc

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Dimension Therapeutics, Inc.

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Bristol-Myers Squibb Company

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. LTE Scientific

11.5. SANOFI

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Applied Genetic Technologies Corp

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. F. Hoffmann-La Roche Ltd.

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Bluebird Bio, Inc.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Novartis AG

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Frequently Asked Questions

The global gene therapy market size was reached at USD 8.69 billion in 2023 and it is projected to hit around USD 51.69 billion by 2033.

The global gene therapy market is growing at a compound annual growth rate (CAGR) of 19.52% from 2024 to 2033.

The North America region has accounted for the largest gene therapy market share in 2023.

Report Details

  • Report Code:37452
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:February 2024
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers